-
Comparing Tongue Strength and Endurance Before and After Eating a Meal
Official Title Impact of Meal Consumption on Lingual EndurancePurpose
The purpose of this study is to understand how eating a meal can affect muscle fatigue in the tongue in individuals with swallowing difficulties due to a neurological disorder or history of a stroke.
If you choose to participate, you will:
- Complete questionnaires about your swallowing and overall health.
- Participate in measurements of your tongue strength using a small, soft bulb placed in your mouth.
- Eat a standard meal of chicken, masked potatoes and green beans.
- Remeasure your tongue and grip strength after the meal
This study is completed in 1 session that lasts approximately 90 minutes.
Could this study be right for you?
- 18 years of age or older
- Report at least some signs/symptoms of difficulty swallowing (dysphagia)
- Have a diagnosed neurological disorder
- English speaking
- Able to eat a standardized meal of chicken, green beans and mashed potatoes
- Adequate dexterity to self-administer foods and drink via fork and cup
Age Range
18 - 100 years -
Evaluating the Efficacy of a Psychedelic Investigational Drug for Patients who are Struggling with Symptoms of Depression and Anxiety due to Cancer or Other Life-Changing Medical Illness
Official Title A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients with Cancer and Other Medical IllnessesPurpose
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Could this study be right for you?
- Depression due to cancer, Parkinson’s, ALS, MS, or IPF
- Currently depressed
- Projected life expectancy of ≥6 months.
Age Range
18 - 80 years -
How Do Ketone Supplements Affect Brain Function in Healthy Adults
Official Title Effects of Acute Ketone Supplementation on the Brain (KETO-BRAIN)Purpose
This study looks at how ketone drinks affect the brain in healthy adults. Ketones are natural substances your body makes when it breaks down fat for energy. Scientists think ketones might help protect the brain and improve how it works.
We want to learn if drinking a ketone supplement changes blood flow to the brain and affects brain chemicals that help with thinking and memory. This information could help us understand if ketone drinks might be helpful for brain health as people age.
If you join this study, you will:
- Come to the research center 3 times over about 1-2 weeks
- Drink either a ketone supplement or a comparison drink (you will not know which one)
- Have brain scans using an MRI machine (like a large medical camera)
- Take simple thinking tests on a computer
- Have finger stick blood tests to measure ketone and sugar levels
You will first come in for a consent visit that take about 1 hour. Then, you will return for two more visits that will take about 3 hours each. You will drink a special beverage twice a day for two days before each scan visit. The study uses MRI scans to safely take pictures of your brain without radiation. We will measure blood flow in your brain and certain brain chemicals before and after you drink the supplement.
This research may help scientists better understand how ketones work in the brain. This could lead to new ways to support brain health in the future.
Could this study be right for you?
Who Can Join:
- Body Mass Index (BMI) between 18.5 and 30
- Able to skip eating overnight before study visits
- Not following a keto diet
Who Cannot Join:
- People who do not speak English
- Currently using ketone supplements or following a keto diet
- Pregnant or breastfeeding
- Allergic to milk protein or lactose intolerant
- History of high blood pressure
- History of alcohol problems in the past 2 years
- History of illegal drug use
- Head injury that caused loss of consciousness
- Brain or nerve disease diagnosis
- Taking medications for mental health conditions
- Current smokers
- Anyone with metal in their body or other reasons they cannot have an MRI scan
Age Range
45 - 65 years -
A Study to Evaluate Investigation Drug, BHV-7000, in Patients with Refractory Focal Onset Epilepsy
Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset EpilepsyPurpose
This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.
People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 4 or more observable focal seizures per month
- Taking at least 1 and up to 3 anti-seizure medications
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months
- Between the ages of 18 to 75
Age Range
18 - 75 years -
Phase 3 Study to Evaluate Investigational Drug, XEN1101, in Patients with Primary Generalized Tonic-Clonic Seizures: XPF-010-303
Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPurpose
In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use. People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 3 PGTCS in an 8-week period
- Have tried at least 2 anti-seizure medications without success
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
- 18 years old and up
Age Range
18 years and up -
Effect of Diet and Electrical Stimulation Exercise on Blood Pressure Control in Spinal Cord Injury
Official Title Lifestyle solutions to postprandial hypotension in spinal cord injuryPurpose
To test if a low-glycemic diet and electrical stimulation of leg muscles can improve blood pressure control after eating.
Could this study be right for you?
- Spinal cord injury sustained at least 1-year ago
- Level of injury between C4 and T10
- Use of wheelchair for majority of daily activities
Age Range
18 years and up -
A First-in-human Study of a New Gene Therapy (AMT-260) in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)Purpose
You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).
The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.
AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.
The overall goals of this study are:
- To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
- To measure if participants have changes in:
- frequency of their seizures
- how their seizures affect their life
- how the human body takes up and removes AMT-260
- To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.
Could this study be right for you?
Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.
Age Range
18 - 65 years -
An Investigational New Drug for the Treatment of Alzheimer’s Disease
Official Title A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Escalating Doses of LH-001 in Healthy SubjectsPurpose
The purpose of this study is to evaluate the safety and tolerability of an investigational new drug in healthy participants aged 18-60 years.
Could this study be right for you?
- In good health and BMI (ratio of body weight to height) between 18-29.9 kg/m2
- Willing to participate in various research assessments including blood collection, urine collection, electrocardiogram, and vital signs
- Willing to stay overnight (~30 hours) in the OSU Hospital Clinical Research Center
- If sexually active, willing to utilize highly effective birth control during the study period
- Not currently pregnant or breast-feeding
- No significant medical condition involving any major organs (heart, lung, liver, brain, or endocrine)
- No to any of the following: alcohol or substance abuse, spleen problems, or drug hypersensitivity
- No history of or undergoing treatment for: major psychiatric illness, seizures, or autoimmune disease
- Not currently taking immunosuppressive drugs
- No active Hepatitis B, Hepatitis C, or HIV
- No cancer history within 5 years (squamous and basal cell skin cancer excluded)
Age Range
18 - 60 years -
Long-term Follow-up of Adults Who Experience an out of Hospital Cardiac Arrest
Official Title Patterns Of Survivors’ Recovery Trajectories in the ICECAP trial POST-ICECAPPurpose
The purpose of this study is to describe the physical, neuropsychological outcomes of adults who have experienced an outside of hospital cardiac arrest; and examine any associations between those outcomes and any clinical and/or rehabilitative interventions and/or social determinants of health.
Could this study be right for you?
- Experienced a coma after resuscitation from a cardiac arrest
- Received targeted/controlled body temperature management
- Survived to at least 1 month after experiencing a outside of hospital cardiac arrest
Age Range
18 years and up -
A Study About Aromatic L-Amino Acid Decarboxylase Deficiency (AADC) in Pediatric Patients
Official Title A Single-Stage, Adaptive, Open-Label Dose Escalation Safety Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MR- guided Infusion into the Midbrain in Pediatric Patients with AADC DeficiencyPurpose
The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency, and to see if there is a demonstration of effective restoration of AADC function by assays of CSF neurotransmitter metabolites and F-DOPA PET imaging, as allowed by subject’s ability to travel to undergo follow-up visits.
Could this study be right for you?
Inclusion Criteria
- Diagnosis of AADC deficiency from genetic test and CSF/blood enzyme test
- Failed to derive adequate benefit from standard medical therapy as judged by presence of residual oculugyric crises and developmental delay.
- Documented history of motor developmental delay, with inability to walk independently without support by age 18 months.
- Both parents (or legal guardians) must give their consent for their child’s participation in the study unless (i.) one parent is deceased, unknown or incompetent; (ii.) one parent is not reasonably available; or (iii.) one parent has responsibility for the care and custody of the child.
Inclusion Criteria varies, please contact Study Coordinator for more information.
Exclusion Criteria
- Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
- Previous stereotactic neurosurgery.
- Coagulopathy, or need for ongoing anticoagulant therapy.
- Receipt of any investigational agent within 60 days prior to Baseline and during study participation.
Exclusion Criteria varies, please contact Study Coordinator for more information.
Age Range
2 years and up